Because GIV is required for the protective effects of MDP/NOD2 signaling in DSS-induced colitis (Figure 5, A-E), we examined whether this protection involves modulation of iColAM and niColAM populations in a GIV-dependent manner. The gene discussed is NOD2; the disease is colitis.